News|Articles|March 15, 2020
- Pharmaceutical Technology-03-15-2020
- Volume 2020 eBook
- Issue 1
A ‘New Normal’ for Quality?
Author(s)Rita C. Peters
With some FDA inspections on hold, will the US drug supply maintain its quality standards?
Advertisement
In February 2020, a report from FDA’s Office of Pharmaceutical Quality (OPQ) noted that, “Quite simply, the quality of our drug supply is better than ever before.” With some FDA inspections on hold, will the US drug supply maintain its quality standards? Plus, which new drug applications must now be filed as biologic license application?
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook and Reference, March 2020
March 2020
Pages: 4–5
Citation
When referring to this article, please cite it as R. Peters, “A “New Normal” for Quality?" Pharmaceutical Technology Regulatory Sourcebook and Reference eBook (March 2020).
Articles in this issue
over 5 years ago
Resources, Guidelines, and Guidance Documentsover 5 years ago
Regulatory and Standard Setting Organizationsover 5 years ago
Monograph Development: Why and When to Participate (eBook)over 5 years ago
A Practical Approach to Pharmacopoeia Compliance (eBook)over 5 years ago
Inside FDA’s New Gene and Cell Therapy Guidancesover 5 years ago
ALCOA+ and Data IntegrityNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
